EBMT 2024 | The prevalence of germline RUNX1 mutations and their impact on alloSCT outcomes

Lea Cunningham • 16 Apr 2024

EBMT 2024

General

Lea Cunningham, MD, National Cancer Institute, Bethesda, MD, discusses a study investigating the prevalence of germline RUNX1 mutations, a cause of familial platelet disorder with associated myeloid malignancies, and their implications for allogeneic stem cell transplantation (alloSCT) outcomes. Among 330 patients analyzed, 6.7% exhibited germline mutations. Compared to patients with somatic mutations, those with germline mutations experienced poorer outcomes, except for those who achieved complete remission (CR) prior to transplantation. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.